Literature DB >> 18684860

Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors.

Africa Gonzalez-Murillo1, M Luz Lozano, Eugenio Montini, Juan A Bueren, Guillermo Guenechea.   

Abstract

Recent studies of retroviral-mediated gene transfer have shown that retroviral integrations themselves may trigger nonmalignant clonal expansion of hematopoietic stem cells (HSCs) in transplant recipients. These observations suggested that previous conclusions of HSC dynamics based on gamma-retroviral gene marking should be confirmed with improved vectors having a more limited capacity to transactivate endogenous genes. Because of the low trans-activation activity of self-inactivating lentiviral vectors (LVs), we have investigated whether the LV marking of mouse HSCs induces a competitive repopulation advantage in recipients of serially transplants. As deduced from analyses conducted in primary and secondary recipients, we concluded that lentivirally transduced HSCs have no competitive repopulation advantages over untransduced HSCs. By linear amplification-mediated polymerase chain reaction (LAM-PCR) analysis, we characterized LV-targeted genes in HSC clones that engrafted up to quaternary recipients. Although 9 clones harbored integrations close to defined retroviral insertion sites, none was characterized as a common integration site, and none was present in HSC clones repopulating quaternary recipients. Taken together, our results show unaltered repopulation properties of HSCs transduced with LVs, and confirm early studies suggesting the natural capacity of a few HSC clones to generate a monoclonal or oligoclonal hematopoiesis in transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684860      PMCID: PMC2569169          DOI: 10.1182/blood-2008-03-142661

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  In vivo gene delivery by lentiviral vectors.

Authors:  L Naldini
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.

Authors:  Suzan Imren; Mary E Fabry; Karen A Westerman; Robert Pawliuk; Patrick Tang; Patricia M Rosten; Ronald L Nagel; Philippe Leboulch; Connie J Eaves; R Keith Humphries
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

3.  Developmental potential and dynamic behavior of hematopoietic stem cells.

Authors:  I R Lemischka; D H Raulet; R C Mulligan
Journal:  Cell       Date:  1986-06-20       Impact factor: 41.582

4.  Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice.

Authors:  J E Dick; M C Magli; D Huszar; R A Phillips; A Bernstein
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

5.  Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.

Authors:  Stephanie Laufs; K Zsuzsanna Nagy; Frank A Giordano; Agnes Hotz-Wagenblatt; W Jens Zeller; Stefan Fruehauf
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

6.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

7.  Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo.

Authors:  P M Challita; D B Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

8.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

9.  Clonal and systemic analysis of long-term hematopoiesis in the mouse.

Authors:  C T Jordan; I R Lemischka
Journal:  Genes Dev       Date:  1990-02       Impact factor: 11.361

10.  Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.

Authors:  Rick S Mitchell; Brett F Beitzel; Astrid R W Schroder; Paul Shinn; Huaming Chen; Charles C Berry; Joseph R Ecker; Frederic D Bushman
Journal:  PLoS Biol       Date:  2004-08-17       Impact factor: 8.029

View more
  11 in total

1.  Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles.

Authors:  Lee S O'Neill; Amy M Skinner; Josha A Woodward; Peter Kurre
Journal:  J Gene Med       Date:  2010-05       Impact factor: 4.565

2.  Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.

Authors:  Olga S Kustikova; Bernhard Schiedlmeier; Martijn H Brugman; Maike Stahlhut; Stefan Bartels; Zhixiong Li; Christopher Baum
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

Review 3.  Genetically engineered mouse models in cancer research.

Authors:  Jessica C Walrath; Jessica J Hawes; Terry Van Dyke; Karlyne M Reilly
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

4.  Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy.

Authors:  Sachiko Kanaji; Erin L Kuether; Scot A Fahs; Jocelyn A Schroeder; Jerry Ware; Robert R Montgomery; Qizhen Shi
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

5.  Modeling the clonal heterogeneity of stem cells.

Authors:  David P Tuck; Willard Miranker
Journal:  Theor Biol Med Model       Date:  2010-11-17       Impact factor: 2.432

6.  Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients.

Authors:  Ariana Jacome; Susana Navarro; Paula Río; Rosa M Yañez; Africa González-Murillo; M Luz Lozano; Maria Luisa Lamana; Julian Sevilla; Teresa Olive; Cristina Diaz-Heredia; Isabel Badell; Jesus Estella; Luis Madero; Guillermo Guenechea; José Casado; Jose C Segovia; Juan A Bueren
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

7.  Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene.

Authors:  Melissa N McCracken; Eric H Gschweng; Evan Nair-Gill; Jami McLaughlin; Aaron R Cooper; Mireille Riedinger; Donghui Cheng; Christopher Nosala; Donald B Kohn; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

8.  Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells.

Authors:  Angel Raya; Ignasi Rodríguez-Pizà; Guillermo Guenechea; Rita Vassena; Susana Navarro; María José Barrero; Antonella Consiglio; Maria Castellà; Paula Río; Eduard Sleep; Federico González; Gustavo Tiscornia; Elena Garreta; Trond Aasen; Anna Veiga; Inder M Verma; Jordi Surrallés; Juan Bueren; Juan Carlos Izpisúa Belmonte
Journal:  Nature       Date:  2009-05-31       Impact factor: 49.962

9.  Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis.

Authors:  Frank Harrison; Brian A Yeagy; Celine J Rocca; Donald B Kohn; Daniel R Salomon; Stephanie Cherqui
Journal:  Mol Ther       Date:  2012-10-23       Impact factor: 11.454

10.  Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding.

Authors:  Rong Lu; Norma F Neff; Stephen R Quake; Irving L Weissman
Journal:  Nat Biotechnol       Date:  2011-10-02       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.